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Key Points
• Specific populations of
activated platelets shed
GPIba and GPVI by
ADAM activity via path-
ways related to, but not
secondary to, PS
exposure.
• ADAM-mediated glyco-
protein shedding in-
creases coagulation
factor binding and en-
hances platelet-
dependent fibrin
formation.
The platelet receptors glycoprotein Iba (GPIba) and GPVI are known to be cleaved by
members of a disintegrin and metalloprotease (ADAM) family (ADAM10 and ADAM17), but
the mechanisms and consequences of this shedding are not well understood. Our results
revealed that (1) glycoprotein shedding is conﬁned to distinct platelet populations showing
near-complete shedding, (2) the heterogeneity between (non)shed platelets is independent
of agonist type but coincides with exposure of phosphatidylserine (PS), and (3) distinct
pathways of shedding are induced by elevated Ca21, low Ca21 protein kinase C (PKC), or
apoptotic activation. Furthermore, we found that receptor shedding reduces binding of von
Willebrand factor, enhances binding of coagulation factors, and augments ﬁbrin formation.
In response to Ca21-increasing agents, shedding of GPIba was abolished by ADAM10/17
inhibition but not by blockage of calpain. Stimulation of PKC induced shedding of only
GPIba, which was annulled by kinase inhibition. The proapoptotic agent ABT-737 induced
shedding, which was caspase dependent. In Scott syndrome platelets that are deﬁcient in
Ca21-dependent PS exposure, shedding occurred normally, indicating that PS exposure is
not a prerequisite for ADAM activity. Inwhole-blood thrombus formation, ADAM-dependent
glycoprotein shedding enhanced thrombin generation and ﬁbrin formation. Together, these
ﬁndings indicate that 2 major activation pathways can evoke ADAM-mediated glycoprotein
shedding in distinct platelet populations and that shedding modulates platelet function
from less adhesive to more procoagulant.
Introduction
In hemostasis and thrombosis, blood platelets are triggered to adhere to an injured or atherosclerotic
vessel wall. Platelet adhesion and subsequent aggregate formation are controlled, in a synergistic way,
by multiple glycoprotein receptors.1-3 Two crucial receptors are glycoprotein VI (GPVI), which interacts
with collagen and fibrin, and GPIb-V-IX, which binds to von Willebrand factor (VWF). Other receptors
with high adhesive strength are CLEC-2 with unknown ligands in the healthy vessel wall; integrin a6b1,
which binds laminin; integrin aIIbb3, which, for example, binds fibrinogen; and integrin a2b1, which also
interacts with collagen.4 Research has indicated that, following activation of the platelets, most, and
perhaps all, of these adhesive receptors can be inactivated, suggesting the presence of postactivation
mechanisms to control platelet interactions with their environment. An example are platelets with high
cytosolic Ca21 levels and phosphatidylserine (PS) exposure, which undergo calpain-dependent
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cleavage of the intracellular integrin b3 chain and adjacent signaling
proteins, resulting in the inactivation of aIIbb3.
5,6 Another example is
cleavage of the extracellular domains of GPIba and GPVI following
platelet stimulation. Studies with inhibitors and murine knockouts
have indicated that the latter cleavage is mediated by 2 members of
a disintegrin and metalloprotease (ADAM) family. It is considered
that GPIba is primarily cleaved by ADAM17, whereas GPVI
shedding is predominantly controlled by ADAM10.7-10 However,
murine studies have indicated significant substrate redundancy
between the 2 ADAM isoforms.11
The literature indicates that ADAM-mediated shedding of the
extracellular domains of GPIba and GPVI can be induced by
a variety of platelet-stimulating agents. These include collagen,
thrombin, the protein kinase C (PKC) stimulus phorbol myristate
acetate (PMA), mitochondrial-uncoupling compounds, and
apoptosis-inducing agents.7,9,11-13 In addition, there is evidence
that shedding of GPIba can be induced at high wall shear rates
or by platelet storage.14,15 It remains unknown which signaling
pathways cause platelets to shed particular glycoproteins. A first
concept, using the compound W7, suggested that platelet ADAM
activity and shedding are negatively regulated by the Ca21-dependent
protein kinase cofactor calmodulin.8,9 Other reports propose that
reactive oxygen species produced in the platelet mitochondria induce
ADAM activation and, hence, receptor shedding.12,16,17 In lympho-
cytes, receptor shedding has been related to phospholipid scram-
bling and PS exposure, which are key processes in apoptosis.18
Together, this suggests the existence of several mechanisms of
ADAM-dependent receptor shedding, likely with consequences for
platelet function.
We hypothesized that 4 distinct pathways can contribute to ADAM-
dependent shedding of GPIba and GPVI: Ca21 elevation, PKC
activation, PS exposure, and caspase activity. Based on this, we
A
*
*
*
Ct
rl
2M
eS
-A
DP
CR
P-
XL Th
r
CR
P-
XL
+T
hr
Ion
om
yc
in
0.0
0.5
1.0
1.5
GP
Ib
 st
ain
ing
(v
s. 
Ct
rl)
B
*
*
Ct
rl
2M
eS
-A
DP
CR
P-
XL Th
r
CR
P-
XL
+T
hr
Ion
om
yc
in
0.0
0.5
1.0
1.5
GP
VI
 st
ain
ing
(v
s. 
Ct
rl)
C
n.s.n.s.
Ct
rl
2M
eS
-A
DP
CR
P-
XL Th
r
CR
P-
XL
+T
hr
Ion
om
yc
in
0.0
0.5
1.0
1.5
GP
IX
 st
ain
ing
(v
s. 
Ct
rl)
D
#
#
vehicle
GW
Ionomycin CRP-XL+Thr
0.0
0.5
1.0
1.5
GP
Ib
 st
ain
ing
(v
s. 
Ct
rl)
E
#
#
Ionomycin CRP-XL+Thr
0.0
0.5
1.0
1.5
GP
VI
 st
ain
ing
(v
s. 
Ct
rl)
F
n.s. n.s.
Ionomycin CRP-XL+Thr
0.0
0.5
1.0
1.5
GP
IX
 st
ain
ing
(v
s. 
Ct
rl)
Figure 1. ADAM10/17-mediated glycoprotein shedding
upon platelet stimulation with strong agonists. Washed
platelets, which were preincubated for 15 minutes with DMSO
(vehicle) or ADAM17/10 inhibitor GW280264X (GW; 5 mM),
were stimulated with 2MeS-ADP, CRP-XL, thrombin (Thr), or
CRP-XL/Thr (GPIba, n 5 8) for 180 minutes or with ionomycin
(GPIba, n 5 8) for 60 minutes (all at 37°C). Unstimulated
platelets were used as control (Ctrl). Staining for GPIba (A,D),
GPVI (B,E), and GPIX (C,F) was measured with optimized
concentrations of FITC anti-GPIba mAb, PE anti-GPVI mAb, or
FITC anti-GPIX mAb using flow cytometry (mean fluorescence
intensities). (A-C) Effect of agonist stimulation on glycoprotein
expression levels. Data are normalized to those of unstimulated
platelets. (D-F) Effect of GW treatment on glycoprotein expres-
sion level. Data are mean 6 SD, n 5 3-5 ($3 donors).
*P , .05 vs unstimulated platelets, #P , .05 vs vehicle.
n.s., not significant.
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used a broad range of potential shedding-inducing agents and
inhibitors to study the involvement of these pathways in specific
populations of activated platelets. Our results indicate that
shedding is regulated on a single-platelet level primarily via Ca21- or
caspase-dependent pathways that are accompanied by, but not
caused by, PS exposure. Furthermore, we examined the conse-
quences of glycoprotein shedding for platelet functional properties.
Materials and methods
Materials
Materials and additional methods are available in the supplemental
Materials and methods.
Blood collection and platelet preparation
Human blood was obtained from healthy volunteers and a patient with
Scott syndrome after informed consent, in accordance with the
Declaration of Helsinki, under protocols reviewed by the local ethics
committee. The Scott syndrome patient was genotyped as compound
heterozygous in ANO6 with 1 mutation, IVS6 1 1G→A, resulting in
exon 6 skipping, and a second mutation (c.1219insT) causing a
premature stop in translation.19
Blood was collected into 3.2% citrate for flow perfusion studies or
into acid-citrate dextrose (1:6 ACD, 80 mM trisodium citrate,
52 mM citric acid, and 180 mM glucose) for platelet isolation. The
first 3 mL of blood was discarded. Washed platelets were prepared
as described before.20 Platelet count was determined with a
Sysmex XP-300 thrombocounter (Sysmex, Chuo-ku Kobe, Japan).
Flow cytometry
Populations of washed platelets (1 3 108/mL) stimulated with
(combinations of) ABT-737 (10 mM), ionomycin (10 mM), convulxin
(100 ng/mL), CRP-XL (5 mg/mL), thrombin (4 nM), SFLLRN
(15 mM), factor Xa (10 mg/mL), 2MeS-ADP (10 mM), CCCP
(100 mM), or PMA (100 nM) were analyzed with an Accuri C6 flow
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Figure 2. Comparable kinetics of glycoprotein receptor shedding and PS exposure in ionomycin-stimulated platelets. Washed platelets, which were preincubated
with vehicle or GW280264X (GW; 5 mM), were left unstimulated (Ctrl) or were stimulated for the indicated times (15 to 300 minutes) with ionomycin (37°C) and evaluated
for glycoprotein expression by flow cytometry. (A-B) ADAM-dependent decrease in surface expression of GPIba and GPVI over time. Mean fluorescence intensities were
normalized to those of unstimulated platelets. (C-D) Analysis of platelet populations after dual staining for GPIba (FITC mAb) or GPVI (PE mAb) and for PS exposure
(AF647-annexin A5). Flow cytometric events were separated into 4 platelet populations: GPIba/VIhigh PS2, GPIba/VIhigh PS1, GPIba/VIlow PS2, and GPIba/VIlow PS1.
Shown are representative dot plots and quantification of 4 quadrants. Data are mean 6 SD, n 5 3-5 ($3 donors). *P , .05 vs control, #P , .05 vs vehicle.
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cytometer and software, as described in detail in supplemental
Materials and methods. Surface expression of GPIba, GPVI, or
GPIX was measured after labeling with a fluorescein isothiocyanate
(FITC) anti-GPIba monoclonal antibody (mAb), phycoerythrin (PE)
anti-GPVI mAb, or FITC anti-GPIX mAb, respectively; AF647-
annexin A5 was added to measure PS exposure. Binding of VWF,
OG488-prothrombin, OG488-factor Xa, or AF488-factor Va was
essentially as described.21
Whole-blood thrombus formation with
platelet activation
Blood was perfused over microspots of collagen type I under
coagulant conditions, as detailed in the supplemental Materials and
methods. Stabilized activated thrombi were stained as indicated
for GPIba (FITC mAb, 2 mg/mL), GPVI (PE mAb, 1 mg/mL), and/or
PS exposure (AF647 annexin A5, 5 mg/mL). Alternatively, platelet
thrombi formed on collagen were used as substrate for thrombin-
generation measurements, as described.22
Statistical analysis
Data are expressed as mean 6 standard deviation (SD) and analyzed
with a paired-sample Student t test. P , 0.05 was considered
significant. Statistical analyses were performed using SPSS Statistics
23 package (IBM, Armonk, NY).
Results
Strong platelet stimulation required for shedding of
GPIba and GPVI
To systematically study the roles of various signaling pathways
implicated in GPIba and GPVI shedding, washed human platelets
were stimulated with a variety of agonists at near-maximal
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Figure 3. Glycoprotein receptor shedding following PS exposure in CRP-XL/thrombin–stimulated platelets. Washed platelets, which were preincubated with
vehicle or ADAM10/17 inhibitor GW280264X (GW; 5 mM), were left unstimulated (Ctrl) or were stimulated with CRP-XL plus thrombin (Thr) for the indicated times and then
evaluated for glycoprotein expression by flow cytometry. (A-B) ADAM-dependent decrease in surface expression of GPIba and GPVI over time. (C-D) Population analysis of
platelets after dual staining for GPIba (FITC mAb) or GPVI (PE mAb) and for PS exposure (AF647-annexin A5). Four platelet populations are defined, as in Figure 2. Note the
gradual increase in the PS-exposing platelet populations and the slower increase in populations with shed GPIba or GPVI. Data are mean 6 SD, n 5 3-7 ($3 donors).
*P , .05 vs control, #P , .05 vs vehicle.
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concentrations and then quantified for staining for the extracellular
domains of GPIba and GPVI using flow cytometry. To check for
possible internalization of the GPIb-V-IX complex, staining for GPIX
was used as a control, because this glycoprotein chain is not
cleaved by ADAM10/17.23 Although platelet stimulation with stable
ADP (2MeS-ADP) did not alter the staining for GPIba, stimulation
with CRP-XL (GPVI receptor agonist) or thrombin (PAR1/4 agonist)
led to a modest reduction (Figure 1A). No reduced staining for GPVI
was observed under these conditions (Figure 1B). For the whole-
platelet population, costimulation with CRP-XL plus thrombin led to
a substantial (60% to 80%) reduction in GPIba and GPVI staining.
This reduction was even more pronounced (.90%) upon
stimulation with the Ca21 ionophore ionomycin (Figure 1A-B). None
of these stimuli affected the staining for GPIX (Figure 1C), thus
excluding interference of internalization of the GPIb-V-IX complex.
Importantly, pretreatment of platelets with the ADAM10/17 inhibitor
GW280264X24,25 essentially abrogated the loss of GPIba and
GPVI staining in platelets stimulated with CRP-XL/thrombin or
ionomycin (Figure 1D-F), thus confirming the involvement of ADAM
extracellular proteases. Other ADAM inhibitors, including
GI254023X (specificity ADAM10. ADAM17) and TAPI (ADAM17
. ADAM10), had similar effects (data not shown).
Population of platelets with PS exposure,
accompanied by GPIba and GPVI shedding
Flow cytometry was also used to assess the kinetics of loss of
surface glycoproteins (inhibitable by GW280264X), as a measure
of receptor shedding, in platelets stimulated with the most active
inducer, ionomycin. For all platelets, 90% of detectable GPIba was
lost after 30 minutes of stimulation, whereas 90% of detectable
GPVI had already disappeared after 15 minutes (Figure 2A-B). This
kinetic difference may be due to the higher copy number of GPIba
in comparison with GPVI expressed per platelet, estimated as
18 800 and 9600 copies, respectively.26 Stimulation of platelets with
ionomycin is known to result in phospholipid scrambling and surface
exposure of PS.27 Considering that membrane destabilization may
trigger ADAM activity, we performed dual staining of platelets for
PS exposure (AF-647 annexin A5) and either GPIba (FITC mAb) or
GPVI (PE mAb) expression. Flow cytometric dot plots confirmed that
the PS-exposing platelets were low in GPIba and GPVI staining
(Figure 2C), although the staining, especially for GPIba, continued
to decrease after full PS exposure (Figure 2D). Pretreatment of
platelets with the ADAM10/17 inhibitor GW280264X blocked
GPIba and GPVI expression changes (Figure 2A-B).
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Figure 4. Normal glycoprotein shedding in Scott syndrome platelets with defective PS exposure. Platelets from a healthy control subject or a Scott patient were
stimulated with 10 mM ionomycin (A), 10 mM ABT-737 (B), 100 ng/mL convulxin and 4 nM thrombin (C), or 100 mM CCCP (D) at 37°C. GPIba expression and PS exposure
were measured at the indicated time points. Platelets were separated into 4 populations (GPIbahigh PS2, GPIbahigh PS1, GPIbalow PS2, and GPIbalow PS1) and quantified.
Data are means of 3 replicates.
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Similar analysis was performed for platelets stimulated with CRP-XL
plus thrombin. These agonists, in comparison with ionomycin, caused a
slower loss of surface-expressed GPIba and GPVI, which continued
for $3 hours. This fluorescence decrease again was antagonized by
GW280264X (Figure 3A-B). Dual-labeling analysis indicated that the
population of PS-exposing platelets appeared before the reduction in
staining for GPIba orGPVI (Figure 3C). Quantification of the platelets
with(out) PS exposure and shed/unshed receptors indicated that, at
an intermediate time of 30minutes, a considerable fraction of platelets
(16% to 44%) with PS exposure still showed appreciable staining for
GPIba and GPVI (Figure 3D). These results are compatible with the
suggestion that platelet exposure to PS is a prerequisite for ADAM-
mediated receptor shedding, such as reported for lymphocytes.18
However, both processes could also occur independently in platelets
that have sensed a certain signal, such as high Ca21.
Glycoprotein shedding can also be evoked by other platelet-activating
agents independently of receptor stimulation. These include the
proapoptotic BH3 mimetic ABT-737,13 also inducing PS exposure28;
the PKC activator PMA7,29; and the mitochondrial-uncoupling agent
CCCP7; the latter two act in an essentially Ca21-independent
way.30,31 Treatment of platelets with ABT-737 resulted in a gradual
(GW280264X-inhibitable) loss of GPIba and GPVI expression,
needing .60 minutes for completion (supplemental Figure 1A-B).
Dual labeling with anti-GPIba mAb and AF647-annexin A5 indicated
that GPIba shedding, at least in part, preceded PS exposure,
whereas GPVI shedding was markedly slower than PS exposure
(supplemental Figure 2A-B). Ultimately, a population of PS-exposing
platelets was formed that had completely lost their glycoproteins.
To exclude microparticle formation as a cause of the loss of
glycoproteins, scatter profiles were determined in the presence of
MegaMix calibration beads. Quantification revealed that the majority
of flow cytometric events (resting, 99.8%; ionomycin, 90.8%) were
comparable in size or had greater forward scatter than the 0.9-mm
beads (supplemental Figure 3). It is noted that the ionomycin-
stimulated cells assume a ballooning morphology, which increases
their size, but also makes them more translucent,32 with likely lower
scatter properties. Furthermore, scatter profiles, in contrast to
glycoprotein levels, were not altered by ADAM inhibition with
GW280264X (supplemental Figure 4).
For the whole-platelet population, stimulation with PMA resulted in only
limited GPIba shedding, which remained incomplete after 5 hours,
whereas GPVI was not shed at all (supplemental Figure 1C-D). Double
labeling indicated that those platelets that had shed GPIba were PS
negative (supplemental Figure 2C-D). Platelet treatment with CCCP
caused even slower shedding, especially of GPVI, requiring up to
5 hours to become measurable (supplemental Figure 1E-F). Also with
CCCP, limited PS exposure was measured. Together, these data
indicated that agonist-induced glycoprotein receptor shedding and PS
exposure occur in the same platelet population, although the different
kinetics indicate that the processes occur independently.
To investigate the relationship between PS exposure and shedding in
more detail, platelets were examined from a Scott syndrome patient,
which aggregate normally but are deficient in PS exposure when
stimulated with Ca21-mobilizing agonists, such as ionomycin or CRP-
XL/thrombin.28,32 Strikingly, the Scott syndrome platelets, regardless
of the stimulus applied (ionomycin, ABT-737, convulxin/thrombin, or
CCCP), displayed high GPIba shedding similarly to platelets from a
control donor (Figure 4). Earlier, we established that these Scott
syndrome platelets show normal agonist-induced Ca21 fluxes.33
Hence, our data suggest that glycoprotein shedding and PS exposure
are Ca21-dependent events but are not mutually dependent.
Pathways of glycoprotein shedding: key roles of
calcium increase and caspase activity
To define the main signaling pathways accountable for receptor
shedding in response to different agents (ionomycin, CRP-XL/
thrombin, ABT-737, PMA, or CCCP), a panel of inhibitors was
applied to block specific pathways. Thus, platelets were pretreated
with calpain inhibitor MDL-28170,5 pan-caspase inhibitor
Q-VD-OPh,28 general PKC inhibitor Ro-318425,34 chelator of
cytosolic Ca21 dm-BAPTA AM,28 or Ca21 entry inhibitor 2APB.35
The combined effects of agonist and inhibitors (supplemental
Table 1) were converted into a heat map, representing the relative
agonist strength to induce GPIba shedding (red) and the inhibitor
efficacy to antagonize this response (blue) (Figure 5). This heat map
identifies the following principal pathways for GPIba shedding: (1)
high Ca21 (inhibited by dm-BAPTA AM, 2APB, or absence of
extracellular CaCl2) in response to ionomycin . CRP-XL/thrombin
. ABT-737, (2) low Ca21 caspase activity (inhibited by Q-VD-OPh)
for ABT-737, and (3) low Ca21 PKC activation (inhibited by
Ro-318425) for PMA . CRP-XL/thrombin. A minor involvement of
calpain was noted for ionomycin-treated platelets.
Heterogeneous shedding of GPIba and GPVI in
platelet thrombi
Because GPIba and GPVI are key receptors in the regulation of
collagen-dependent thrombus formation under flow,1,4 it was
reasoned that ADAM-mediated cleavage of the glycoproteins may
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Figure 5. Analysis of signaling pathways implicated in agonist-induced
glycoprotein shedding. Washed platelets were pretreated with ADAM10/17
GW280264X, the calpain inhibitor MDL-28170, the pan-caspase inhibitor Q-VD-OPh, the
general PKC inhibitor Ro-318425, the Ca21 chelator dm-BAPTA AM, or the Ca21 entry
inhibitor 2APB. Samples were stimulated with ionomycin/CaCl2, CRP-XL plus thrombin,
PMA, ABT-737, or CCCP, as indicated. Data are normalized to those of unstimulated
platelets without any inhibitors. Shown is a heat map representing the effects of agonists on
GPIba shedding (red), as well as relative antagonizing effects of inhibitors (blue). Note the 3
clusters representing a role for Ca21 elevation (i), caspase activation (ii), and PKC activity (iii).
See supplemental Table 1 for additional information.
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affect the adhesion of platelets to aggregates or thrombi. To examine
this, platelet thrombi were allowed to form on collagen under
coagulant conditions. In this setting, thrombi are known to consist
of 2 populations of platelets: pseudopod-containing platelets in
aggregates and patches of balloon-shaped PS-exposing platelets
surrounding the aggregates.1,36 For the aggregated platelets, no
difference was seen in staining for GPIba or GPVI expression, even
after 3 hours of incubation (Figure 6). In contrast, the balloon-shaped
PS-exposing platelets no longer stained for GPIba or GPVI and were
loosely connected to the thrombi.
Incubation of thrombi in the presence of GW280264X retained the
staining for GPIba and GPVI of the balloon-shaped PS-exposing
platelets. Exposure of PS was not affected by GW280264X
treatment (9.4%6 3.0% surface area coverage [SAC] vs 12.1%6
6.8% SAC for controls, mean 6 SD, n 5 3, P 5 .39). When the
thrombi on collagen were postactivated with ionomycin, the number
of loosely adhered PS-exposing platelets markedly increased,
whereas staining for GPIba and GPVI decreased (supplemental
Figure 5). Again, the latter decrease, in contrast to PS exposure,
was antagonized by GW280264X. This confirmed the hypothesis
that only the high-Ca21 PS-exposing platelets in thrombi had lost
their GPIba and GPVI receptors via ADAM10/17-mediated
shedding (ie, platelets with loose adherence to collagen or thrombi).
Functional effects of glycoprotein shedding
Additional studies were performed to determine the functional
effects of GPIba and GPVI shedding in the population of high-Ca21
platelets. In addition to reducing platelet-adhesive properties,
removal of the extracellular domain of these abundantly expressed
glycoproteins may affect the binding properties of plasma proteins,
such as coagulation factors. To investigate this, washed platelets
were stimulated with ionomycin, ABT-737, or CRP-XL/SFLLRN
(replacing thrombin, to prevent fibrin formation), which resulted in
GPIba and GPVI shedding, and were then evaluated for binding
properties by flow cytometry. It appeared that all agonists reduced
VWF binding (Figure 7Ai), a VWF receptor in accordance with
the lower level of extracellular GPIba. Notably, preincubation of
platelets with GW280264X or the 5G6 Fab fragment, which blocks
the ADAM17 cleavage site in GPIba,10 almost completely restored
VWF binding.
Considering the fact that PS-exposing platelets bind coagula-
tion (co)factors of the prothrombinase complex,21 we assessed
platelets, stimulated with ionomycin, ABT-737, or CRP-XL/
SFLLRN, for binding of fluorescent-labeled prothrombin, factor
Xa, and factor Va. As expected, the population of PS-exposing
platelets showed strong staining for all these coagulation factors.
Inhibition of ADAM activity with GW280264X resulted in a partial
reduction in binding, which was significant for most of the agonists
(Figure 7Aii-iii). Essentially similar results were obtained with 2 other
ADAM inhibitors: GI254023X (specificity ADAM10 . ADAM17)
and TAPI (ADAM17 . ADAM10) (supplemental Figure 6).
Furthermore, the 5G6 Fab fragment, which inhibited GPIba
shedding, also had a suppressive effect on coagulation factor
binding (Figure 7Aii-iii).
Evidence has been provided for a role of factor Xa in the shedding
of GPVI but not GPIba.37 To evaluate this in the present setting,
platelets were treated with unlabeled factor Xa and then stimu-
lated with thrombin and/or CRP-XL. However, no (enhancing) effect
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Figure 6. Selective loss of GPIba and GPVI in high-Ca21
PS-exposing platelets in thrombi. Platelet thrombi were formed
in flow chambers on collagen type I using whole-blood perfusion at
a wall shear rate of 1000 s21. The thrombi were postactivated with
thrombin, incubated with vehicle or GW280264X (GW) for up to
180 minutes at 37°C, and stained for GPIba and GPVI expression
and PS exposure. (A) Representative confocal fluorescence images
of GPIba and GPVI expression and PS exposure. PS-exposing
ballooned platelets are indicated by arrows and arrowheads. (B)
Regions of interest corresponding to aggregated platelets and
ballooned platelets were analyzed for fluorescence staining. Pixels
representing GPIba2 or GPVI1 platelets were determined and
expressed as percentages of surface area coverage of ballooned or
aggregated platelets. Data are mean 6 SD, n 5 3. *P , .05.
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Figure 7. Glycoprotein shedding increases coagulation factor binding to platelets and enhances the formation of thrombin and fibrin. (A) Washed platelets were
preincubated with vehicle, GW280264X (GW; 5 mM, 15 minutes), or 5G6 Fab fragment, which are known to block ADAM17-mediated shedding of GPIba (10 mg/mL, 15 minutes).
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of factor Xa on GPIba or GPVI staining could be determined
(supplemental Figure 7).
Also in thrombi on collagen, PS-exposing platelets bind pro-
thrombin.21 Using OG488-prothrombin, this was confirmed for
thrombi posttreated with SFLLRN and incubated at 37°C to allow
receptor shedding (Figure 7Bi-ii). Notably, ADAM inhibition with
GW280264X lowered the prothrombin binding at (high-Ca21) PS-
exposing platelets, which is in line with the flow cytometry results.
Again, annexin A5 staining was not affected by GW280264X.
Staining for VWF revealed a lower level on PS-exposing platelets
(data not shown), again in agreement with the requirement of
noncleaved GPIba for VWF binding.
To further assess whether the altered coagulation factor binding to
platelets had functional consequences, kinetics of thrombin and fibrin
was examined. Thrombi posttreated with SFLLRN, containing
platelets with shed glycoproteins (incubation at 37°C), were perfused
with recalcified plasma. Subsequent thrombin-generation measure-
ments with the thrombin substrate Z-GGR-AMC indicated a gradual
accumulation of thrombin activity, which was partly suppressed upon
inhibition of receptor shedding by GW280264X (Figure 7Biii).
Control experiments with plasma confirmed that this ADAM inhibi-
tor, similar to other ADAM inhibitors, was without effect on the
thrombin-generation process per se (data not shown). In addition,
when collagen-adhered platelets with maximally shed receptors (by
ionomycin stimulation) were superfused with recalcified plasma,
fibrin formation was markedly delayed in the presence of
GW280264X (Figure 7C). Taken together, these results indicated
that the Ca21-induced glycoprotein shedding of platelets is
accompanied by a moderate increase in coagulation factor binding
and enhanced thrombin and fibrin generation, which augment the
platelet procoagulant phenotype.
Discussion
In this article, we provide new evidence for heterogeneity between
populations of activated platelets with regard to the ADAM10/17-
mediated shedding of extracellular GPIba and GPVI. Flow
cytometry revealed platelet populations with either near-complete
glycoprotein shedding or without shedding, irrespective of the
agonist used. The following shedding-promoting pathways were
identified: (1) persistent Ca21 increase (eg, induced by collagen/
thrombin receptor stimulation or ionomycin), accompanied by, but
not secondary, to PS exposure and ballooning; (2) low-Ca21 PKC
stimulation; and (3) caspase-mediated apoptosis, evoked by the
BH3 mimetic ABT-737 and in this case preceding PS exposure.
Our data further indicate that shedding of GPIba was unaltered
in platelets from a Scott syndrome patient, which are character-
ized by defective PS exposure but no other affected platelet
responses.32,38 Although the populations of shed and PS-exposing
platelets can overlap, we concluded that the major membrane
disturbance upon PS exposure and balloon formation is not a
prerequisite for ADAM-mediated proteolysis. Rather, it appears that
both processes share a common denominator, such as elevated
Ca21, upstream in the regulatory pathways (supplemental Figure 8).
Thus, our data with platelets deviate from a recent report
on lymphocytes, in which PS exposure was considered to be
upstream of ADAM17 activity.18
A surprising finding was that ADAM-induced glycoprotein shed-
ding arises as an all-or-nothing event. This was concluded from
the observations that shedding of the 2 glycoproteins, GPIba (via
ADAM17) and GPVI (via ADAM10), (1) occurs in the same
population of platelets, regardless of the agonist type (with PMA as
an exception, see later discussion), and (2) proceeds in single
platelets to near completion, thus leading to a marked separation of
populations with shed or nonshed receptors. The well-characterized
ADAM10/17 inhibitor GW280264X almost completely inhibited this
process, similar to the ADAM inhibitor GI254023X (5 mM, ;80%),
whereas common matrix metalloproteinase inhibitors were without
effect (data not shown). One can speculate that residual protein
cleavage can be due to other ADAM isoforms (eg, ADAM9, which is
expressed at 600 copies per platelet).26
Previous investigations have shown that the isoforms ADAM10 and
ADAM17 can cleave multiple platelet glycoproteins with at least
partial redundancy.9 Yet, ADAM17 was found to preferentially
cleave, similar to GPIba, JAM-A, tetraspanin 9, and semaphorins,
whereas ADAM10 preferentially shed GPVI and CD84.29,39 This
substrate specificity might depend on the type of agonist, but this
has not been clarified.11 In terms of the mechanism of ADAM-
mediated glycoprotein shedding, other investigators have proposed
an inhibitory role for calmodulin9 and a stimulating role for the p38
MAPK pathway,14 although the direct activation mechanism of the
ADAM proteases in platelets is still unclear.40,41 Our data point to
a positive, rather than a negative, role for elevated cytosolic
Ca21 in glycoprotein shedding, suggesting the involvement of a
Ca21-dependent protease activator.
In individual platelets, GPIba and GPVI appeared to be cleaved to
the same extent, independently of the type of agonist; PMA, which
preferentially shed GPIba, was a notable exception. The latter
observation may imply a specific PKC-dependent activation pattern
for ADAM17, with GPIba as the preferred substrate. This
suggestion is in line with observations from murine embryonic
fibroblasts, showing that PKC activation does not activate
ADAM10.42 Our data further point to a limited cross talk between
the Ca21-dependent and caspase-dependent activation path-
ways, because chelation of cytosolic Ca21 resulted in only limited
Figure 7. (continued) After 60 minutes of stimulation (37°C) with ionomycin, ABT-737, or CRP-XL plus SFLLRN, flow cytometry was used to measure platelet binding of VWF with
fluorescent anti-VWF mAb (in the presence of ristocetin) (Ai), OG488-prothrombin (Aii), OG488-factor Xa (Aiii), or AF488-factor Va (Aiv). Binding of prothrombin, factor Xa, and factor
Va was evaluated for the PS-exposing platelet population, identified with AF647-annexin A5. Data are mean 6 SD, n 5 3-6. (B) Platelet thrombi were formed on collagen and
posttreated with SFLLRN for 60 minutes at 37°C in the presence of vehicle or GW (5 mM). After incubation, the thrombi were stained with OG488-prothrombin or were incubated with
recalcified plasma supplemented with fluorogenic substrate Z-Gly-Gly-Arg-AMC to measure thrombin generation. Representative fluorescence images (Bi) and quantification of
prothrombin fluorescence (Bii). (Biii) Time course (under stasis) of generation of thrombin from the surface of platelet thrombi formed in the presence or absence of GW. Data are
mean 6 SD, n 5 3. (C) Kinetics of fibrin formation at a layer of adhered platelets on collagen, posttreated with ionomycin for 10 minutes, and inducing maximal shedding, in the presence
of vehicle or GW. Fibrin formation was then allowed by perfusion of recalcified normal plasma at 250 s21, while recording fluorescence images. Shown are times to fibrin formation
and representative time traces of fibrin formation (expressed as SAC). Data are mean 6 SD, n 5 6. *P , .05.
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inhibition of shedding in apoptotic platelets. This is in line with earlier
observations that ABT-737 primarily acts independently of Ca21,
although in a small platelet population it can cause increases in
Ca21.28 Shedding induced via PMA seems to be essentially Ca21
independent, because PMA in platelets strongly suppresses
agonist-induced increases in Ca21.30,31
In thrombi formed ex vivo with aggregated and procoagulant platelets,
ADAM-mediated glycoprotein shedding was also concentrated on
ballooned platelets with PS exposure. This agrees with observations
from other investigators that thrombi formed under flow conditions are
high in ADAM10 activity.43 Furthermore, under conditions of shedding,
regardless of agonist type, the binding of VWF to platelets decreased,
whereas the binding of coagulation factors increased. Platelet PS
exposure is known to be accompanied by less adhesion due to calpain-
induced integrin cleavage.5 The present data add to this and indicate
that such procoagulant platelets, with shed receptors, are defective in
establishing GPIba- and GPVI-dependent interactions (eg, to VWF,
collagen, and fibrin).44-46 In addition, GPIba provides a binding site for
a-thrombin.47 However, this binding does not seem to play a role in the
generation of thrombin and fibrin at PS-exposing platelets, given the
rapid shedding of GPIba from such platelets.
In terms of functional effects, our results point to a moderate
enhancement of thrombin generation and fibrin formation under
conditions of extensive glycoprotein shedding. Taken together, the
present data indicate that (1) there is substantial heterogeneity in
ADAM-induced glycoprotein shedding between activated plate-
lets, and that (2) the platelet population with (near-complete)
glycoprotein shedding has altered functional properties. Thus,
the platelets undergoing ADAM-induced glycoprotein shedding
seem to undergo a phenotypic change from less-adhesive platelets
to more-procoagulant platelets. Although this study concentrated
on GPIba and GPVI, the broader substrate spectrum of platelet
ADAM isoforms may suggest that the revealed changes are
exemplary of a broader phenotypic change.
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